pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,922 catalysts · 4,876 phase readout · 2,367 8k filing · 286 earnings · 275 pdufa · 138 phase 2 completion · 64 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,876
  • 8k filing2,367
  • earnings286
  • pdufa275
  • phase 2 completion138
  • phase 1 completion64
  • phase 1 initiation39
  • phase 2 initiation35
  • phase 1 2 completion29
  • phase 0 trial completion22
  • therapy area
    • Oncology122
    • Infectious Disease36
    • Cardiology33
    • Immunology25
    • Dermatology21
    • Pulmonology16
    • Ophthalmology12
    • Women's Health11
    • Pain10

    Week of Apr 27, 2026

    50
    ›Apr 29, 20268k filing89d ago$LUNG — Pulmonx Corp (LUNG) — 8-K filing

    Items: 2.02

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$PRCT — PROCEPT BioRobotics Corp (PRCT) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$BDX — BECTON DICKINSON & CO (BDX) — 8-K filing

    Items: 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$IVF — INVO Fertility, Inc. (IVF) — 8-K filing

    Items: 3.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$CBIO — CRESCENT BIOPHARMA, INC. (CBIO) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$BHC — Bausch Health Companies Inc. (BHC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$HIND — Vyome Holdings, Inc (HIND) — 8-K filing

    Items: 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$VKTX — Viking Therapeutics, Inc. (VKTX) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$BBOT — BridgeBio Oncology Therapeutics, Inc. (BBOT) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$SDEV — Stablecoin Development Corp (SDEV) — 8-K filing

    Items: 4.02

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d agoTriSalus Life Sciences, Inc. (TLSI, TLSIW) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$OLMA — Olema Pharmaceuticals, Inc. (OLMA) — 8-K filing

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$ASRT — Assertio Holdings, Inc. (ASRT) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$CTXR — Citius Pharmaceuticals, Inc. (CTXR) — 8-K filing

    Items: 3.02, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$CTOR — CITIUS ONCOLOGY, INC. (CTOR) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$PMHS — Polomar Health Services, Inc. (PMHS) — 8-K filing

    Items: 1.02, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d agoProfusa, Inc. (PFSA, NVACW) — 8-K filing

    Items: 1.01, 2.03, 3.01, 3.03, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 20268k filing89d ago$AUTL — Autolus Therapeutics plc (AUTL) — 8-K filing

    Items: 2.05, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 2026constraining patent expiry europe88d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026patent expiry88d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting88d agoAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)camizestrant

    Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

    full page →camizestrant →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting88d agoAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)capivasertib

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer

    full page →capivasertib →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoSarepta Therapeutics Inc — golodirsen (NDA/BLA Filing (US))golodirsen

    Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy

    full page →golodirsen →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026pdufa88d agoAxsome Therapeutics Inc — (bupropion hydrochloride + dextromethorphan) ER (PDUFA)(bupropion hydrochloride + dextromethorphan) ER

    Therapy area: Central Nervous System. Indication: Dementia Associated With Alzheimer's Disease

    full page →(bupropion hydrochloride + dextromethorphan) ER →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoKunming Yan'an Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Pain

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoAffiliated Hospital of Xuzhou Medical University — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Delirium

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →insulin →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

    Therapy area: Dermatology. Indication: Pressure Ulcers

    full page →Aquacel Ag + →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoYangzhou No.1 People's Hospital — dexamethasone (Phase 0 Trial Completion)dexamethasone

    Therapy area: Gastrointestinal. Indication: Post Operative Nausea And Vomiting

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoHefei First People’s Hospital — ergothioneine (Phase 0 Trial Completion)ergothioneine

    Therapy area: Cardiovascular. Indication: Atherosclerosis

    full page →ergothioneine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoAffiliated Hospital of Xuzhou Medical University — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Delirium

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoUniversity of Utah — micronized progesterone (Phase 0 Trial Completion)micronized progesterone

    Therapy area: Central Nervous System. Indication: Substance (Drug) Abuse

    full page →micronized progesterone →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoAffiliated Hospital of Xuzhou Medical University — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System. Indication: Delirium

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoNational Key Research and Development Program — undisclosed sodium glucose cotransporter 2 inhibitor (Phase 0 Trial Completion)undisclosed sodium glucose cotransporter 2 inhibitor

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →undisclosed sodium glucose cotransporter 2 inhibitor →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoUniversity of Southern California — methylprednisolone (Phase 0 Trial Completion)MEDROL

    Therapy area: Immunology. Indication: Drug Hypersensitivity Reactions

    full page →MEDROL →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoKey Projects of Science and Technology Department of Sichuan Province — dantrolene (Phase 0 Trial Completion)dantrolene

    Therapy area: Cardiovascular. Indication: Ischemia, Myocardial Ischemia, Ventricular Arrhythmia

    full page →dantrolene →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoBaylor College of Medicine — glycine (Phase 0 Trial Completion)glycine

    Therapy area: Central Nervous System. Indication: Alzheimer's Disease

    full page →glycine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoUniversity of Pennsylvania — ubidecarenone (Phase 0 Trial Completion)ubidecarenone

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Crohn's Disease (Regional Enteritis), Fatigue

    full page →ubidecarenone →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoJiangsu Maoxing Technology Co Ltd — MT-026 (Phase 0 Trial Completion)MT-026

    Therapy area: Oncology. Indication: Glioma

    full page →MT-026 →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoFirst Affiliated Hospital of Anhui Medical University — esketamine (Phase 0 Trial Completion)esketamine

    Therapy area: Central Nervous System, Oncology. Indication: Post-Operative Pain, Thyroid Cancer

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoInner Mongolia Aerospace Hospital — (bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) (Phase 0 Trial Completion)(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12)

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Atherosclerosis, Irritable Bowel Syndrome

    full page →(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoFuning County People's Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post Operative Nausea And Vomiting, Post-Operative Pain

    full page →dexmedetomidine →source: globaldata
    ← prev
    page 6 of 159
    next →
    $AZN169.26+0.59%
    $AXSM241.00-0.22%
    $SRPT15.68-1.26%
    $AZN169.26+0.59%
    $CPIX6.6100-5.37%